Output
VHPB publications/reports
|
The elimination of hepatitis D as a public health problem: Needs and challenges. Vanwolleghem T, Armstrong PA, Buti M, FitzSimons D, Valckx S, Hendrickx G, Van Damme P. J Viral Hepat. 2023 Oct 3. doi: 10.1111:jvh.13891
|
||
| Andani A, van Damme P, Bunge EM, Salgado F, van Hoorn RC, Hoet B. Vaccine. 2022 Jan 21;40(2):196-205. doi: 10.1016/j.vaccine.2021.01.038. |
||
| Epub 2021 Jan 30. PMID: 33526283. |
||
| Developing and Piloting a Standardized European Protocol for Hepatitis C Prevalence Surveys in the General Population (2016-2019). | ||
| Sperle I, Nielsen S, Bremer V, Gassowski M, Brummer-Korvenkontio H, Bruni R, Ciccaglione AR, Kaneva E, Liitsola K, Naneva Z, Parchemlieva T, Spada E, Toikkanen SE, Amato-Gauci AJ, Duffell E, Zimmerman R on behalf of the SPHERE-C Expert Group. | ||
| Front. Public Health, 28 May 2021; doi: 10.3389/fpubh.2021.568524 | ||
| Many European countries ‘flying blind’ in their efforts to eliminate viral hepatitis. | ||
| Lazarus JV, Safreed-Harmon K, Colombo M, Reic T, Schatz E, Van Damme P; ACHIEVE Coalition. | ||
| Nat Rev Gastroenterol Hepatol. 2017 Jul 26;14(8):445-446. doi: 10.1038/nrgastro.2017.98. | ||
| Single-Dose Hepatitis A Immunization: 7.5-Year Observational Pilot Study in Nicaraguan Children to Assess Protective Effectiveness and Humoral Immune Memory Response. | ||
| Mayorga O, Bühler S, Jaeger VK, Bally S, Hatz C, Frösner G, Protzer U, Van Damme P, Egger M, Herzog C. | ||
| J Infect Dis. 2016 Nov 15;214(10):1498-1506 | ||
| Innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries: a roundtable meeting report. | ||
| David FitzSimons, Greet Hendrickx, Johannes Hallauer, Heidi Larson, Daniel Lavanchy, Ina Lodewyckx,Daniel Shouval, John Ward and Pierre Van Damme. | ||
| Hepatology, Medicine and Policy; 2016, 1:16. DOI 10.1186/s41124-016-0022-8 | ||
| Editorial on “What is a potentially damaging vaccination delay in children younger than 2 years?” |
| Kane MA, Roudot-Thoraval F, Guerin N, Papaevangelou V, Van Damme P; Viral Hepatitis Prevention Board. |
| Hum Vaccin Immunother. 2016 Aug 2;12(8):2053-2056. |
| A hepatitis-free future: strategy first, then pricing. | ||
| Heidi Larson, Pierre Van Damme & David FitzSimons | ||
| Lancet Infect Dis & 2016, 16(4):399-400. doi: 10.1016/S1473-3099(16)00126-2. | ||
| Editorial on “What is a potentially damaging vaccination delay in children younger than 2 years?” | ||
| Mark A. Kane, Francois Roudot-Thoraval, Nicole Guerin, Vassiliki Papaevangelou, Pierre Van Damme & on behalf of the Viral Hepatitis Prevention Board | ||
| Human Vaccines & Immunotherapeutics 2016, DOI:10.1080/21645515.2016.1177689 | ||
| Long-term Protection After Hepatitis B Vaccine | ||
| van Damme P | ||
| J Infect Dis. 2016, doi: 10.1093/infdis/jiv750 | ||
| Prevalence of HBV and HCV among outpatients in the plovdiv region of Bulgaria,2010-2011 | ||
| Kevorkyan A1, Teoharov P, Lernout T, Petrova N, Raycheva R, Ivanov I, van Damme P, Kojouharova M. | ||
| J Med Virol 2015,87: 401-406 | ||
| A cohesive European policy for hepatitis B vaccination, are we there yet? | ||
| Lernout T, Hendrickx G, Vorsters A, Mosina L, Emiroglu N, Van Damme P. | ||
| Clin Microbiol Infect 2014,20 Suppl 5: 19-24 | ||
| Viral Hepatitis Prevention B. Reduced prevalence of HBsAg variants following a successful immunization program in China. | ||
| Jilg W, Norder H, Kane M, Van Damme P, Vorsters A. | ||
| J Virol 2014, 88: 4605-4606 | ||
| Incentives and barriers regarding immunization against influenza and hepatitis of health care workers. | ||
| Meeting report Barcelona | ||
| FitzSimons D, Hendrickx G, Lernout T, Badur S, Vorsters A, Van Damme P. | ||
| Vaccine 2014, 32: 4849-4854 | ||